市场调查报告书
商品编码
1422079
分子标靶诊断市场:产品与服务,样本类型,测试类型,技术,应用,最终用户,地区,机会,预测2017-2031 年Molecular Targeted Diagnostics Market Assessment, By Product & Service, By Sample Type, By Test Type, By Technology, By Application, End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球分子标靶诊断市场规模预计将从 2023 年的 147.5 亿美元增至 2031 年的 254.7 亿美元,预测期内复合年增长率为 7.07%。 全球分子标靶诊断市场的成长和演变是由伴随诊断需求不断增长、技术进步、慢性病扩散、个人化医疗的出现、政府措施和不断增加的研发投资等因素所推动的。关键驱动因素之一是对伴随诊断的需求不断增长。伴随诊断透过识别有助于预测治疗效果的特定生物标誌物,在针对个别患者制定治疗方案方面发挥重要作用。此外,技术的不断进步开发出了准确性和精确度不断提高的先进诊断工具,推动了分子标靶诊断市场的扩张。癌症、心血管疾病和传染病等慢性疾病的盛行率不断上升,增加了可靠诊断技术的需求。此外,个人化医疗的出现正在彻底改变医疗保健,强调根据个人的基因组成和特定生物标记量身定制的治疗方法。
个人化医疗的出现是推动分子标靶诊断市场的关键因素。这种方法根据患者独特的基因谱、生物标记和特征量身定制治疗。精准诊断工具,例如分子标靶诊断,对于识别特定的基因改变和生物标记非常重要,而这些基因改变和生物标记对于确定治疗策略非常重要。这些诊断工具透过指导针对性治疗、预测治疗结果和提高患者反应发挥关键作用。
研发资金的增加正在推动诊断技术的技术发展。这些财务投资正在帮助开发更准确、更有效率、更广泛可用的诊断工具。此外,它还有助于验证和批准复杂的诊断测试,并且其在各个医疗保健领域的使用正在扩大。资金的增加透过提高诊断准确性和有效性,极大地促进了市场扩张,最终促进了更广泛的患者护理的改善。
本报告调查了全球分子标靶诊断市场,并提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构、影响市场增长的因素分析以及案例研究。 、主要公司简介等
Global molecular targeted diagnostics Market size was valued at USD 14.75 billion in 2023 which is expected to reach USD 25.47 billion in 2031 with a CAGR of 7.07% for the forecast period between 2024 and 2031. Various factors propel the growth and evolution of the global molecular targeted diagnostics market. Some of the drivers are growing need for companion diagnostics, advancements in technology, a surge in prevalence of chronic diseases, the emergence of personalized medicine, governmental initiatives, and increasing investment in research & development. One of the key drivers of global molecular targeted diagnostics market is the increasing demand for companion diagnostics, which plays a crucial role in tailoring treatments to individual patients by identifying specific biomarkers that assist in predicting treatment responses. Moreover, continuous advancements in technology have led to the development of advanced diagnostic tools that offer enhanced accuracy and precision, fostering the expansion of global molecular targeted diagnostics market. The increasing prevalence of chronic diseases including cancer, cardiovascular diseases, and infectious ailments, has amplified the necessity for reliable diagnostic techniques. Furthermore, the emergence of personalized medicine has revolutionized healthcare by emphasizing treatments tailored to an individual's genetic makeup and specific biomarkers.
Government initiatives supporting precision medicine and healthcare infrastructure expansion, coupled with increasing awareness and patient empowerment regarding the benefits of early diagnosis and targeted treatments, have significantly propelled the adoption of molecular targeted diagnostics. Additionally, significant investments in research and development by pharmaceutical and biotech companies aim to innovate and improve diagnostic tools, fostering growth in global molecular targeted diagnostics market by enhancing accuracy, efficacy, and accessibility.
The emergence of personalized medicine is a pivotal driver propelling the global molecular targeted diagnostics market. This approach tailors' treatments according to patients' unique genetic profiles, biomarkers, and characteristics. Precision diagnostic tools, like molecular targeted diagnostics, are important for identifying specific genetic alterations and biomarkers critical for determining treatment strategies. These diagnostics tools serve a crucial role by guiding targeted therapies, forecasting treatment outcomes, and enhancing patient responses. As the demand increases for personalized treatments that cater to individual patient needs, the importance of personalized medicine will also increase. Consequently, this surge in significance fuels the broader adoption and utilization of molecular targeted diagnostics across various healthcare settings worldwide. This symbiotic relationship between personalized medicine and molecular targeted diagnostics signifies a transformative shift toward more individualized and effective patient care strategies within the global healthcare landscape.
Technological developments in diagnostic technologies are being driven by increased funding for research and development. These financial investments help develop more accurate, efficient, and widely available diagnostic tools. Additionally, they assist in validating and approving complicated diagnostic tests, broadening their usage across various healthcare domains. This increased funding substantially contributes to the market's expansion by improving diagnostic precision and effectiveness and, ultimately, fostering enhanced patient care on a larger scope. In August 2023, significant financial support was given to researchers at the City of Hope Medical Centre in California to develop a novel targeted chemotherapy. The new targeted chemotherapy showed promising results against all solid tumors in preclinical studies. Targeting proliferating cell nuclear antigen (PCNA), a protein that had been "undruggable," the novel drug candidate AOH1996 appears to eliminate all solid tumors related to PCNA.
In situ hybridization (ISH) serves a critical function by allowing visualization and recognition of precise nucleic acid sequences within cells or tissues. This method assists in identifying gene expressions, changes, or disease-causing components, thereby aiding precise disease identification and tailored treatment approaches. As healthcare prioritizes targeted and personalized therapies more, the increased demand for precise molecular diagnostics, notably ISH, fosters the growth of global molecular targeted diagnostics market. This demand facilitates accurate identification and understanding of biomarkers, elevating diagnostic capacities across different diseases globally. In May 2023, Bio-Techne, revealed enhancements in advanced cell diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) range. This extension involves the introduction of an RNAscope multiomic workflow designed for the Standard BioTools Hyperion Imaging System.
Governments actively participate in initiatives to enhance molecular targeted diagnostics by creating specialized research hubs. These initiatives are intended to progress research, foster innovation, and encourage the adoption of state-of-the-art diagnostic technologies. By nurturing environments conducive to research and development, these undertakings drive the growth and development of the global molecular targeted diagnostics market. These coordinated government initiatives stimulate technological progress and endorse the validation and assimilation of innovative diagnostic instruments, ultimately augmenting healthcare capabilities and advancing the quality of patient care globally. For instance, in August 2023, Kalyan Singh Super Specialty Cancer Institute (KSSSCI), a distinguished establishment operated by the Government of Uttar Pradesh, collaborated with Karkinos Healthcare and the Indian Institute of Technology Kanpur. This impactful three-way alliance signifies the launch of the 'Centre for Advanced Molecular Diagnostics and Research for Cancer (CAMDRC)', slated to be established in Lucknow.
The rising demand for infectious disease diagnostics acts as a fundamental force propelling the global molecular targeted diagnostics market. This increase in demand arises from the essential need for precise, swift, and specialized diagnostic instruments to detect viruses, bacteria, or parasites accurately. Molecular targeted diagnostics is responsible for promptly identifying and characterizing these infectious agents, allowing for timely treatment choices and strategies to control infections. With persistent challenges posed by infectious diseases in the global healthcare scenario, the amplified necessity for accurate diagnostic tools drives the worldwide expansion and uptake of molecular targeted diagnostics. In April 2023, Thermo Fisher Scientific introduced the inaugural set of 37 CE-IVD-marked real-time PCR assay kits. Primarily designed for diagnosing infectious diseases, these kits are part of the company's plan to unveil a total of 37 such kits within the year. This launch signifies the introduction of Thermo Fisher Scientific's own company-branded test kits, enabling users of its QuantStudio Dx series of instruments to access a diverse range of testing options for the first time.
The future expansion prospects of the global molecular targeted diagnostics market are substantial. Technological advancements, especially in genomics, proteomics, and molecular biology, pave the path for more refined and thorough diagnostic tools. The rising prevalence of chronic illnesses, infectious diseases, and cancer cases on a global scale fuels the need for early detection and personalized therapies, fostering the adoption of molecular targeted diagnostics. Furthermore, the paradigm shifts toward personalized medicine, focusing on customized treatments rooted in individual genetic profiles, intensifies the demand for precise diagnostic methods. Ongoing investments in research and development by pharmaceutical and biotech firms aim to innovate and refine diagnostic precision. Government initiatives backing precision medicine and healthcare infrastructure also play pivotal roles in market growth. As healthcare professionals and patients become increasingly aware of the advantages of early diagnosis, the global molecular targeted diagnostics market is positioned for substantial expansion, leading to improved patient care and treatment outcomes worldwide.
Many companies in the global molecular targeted diagnostics market are actively participating in strategic partnerships. These alliances seek to merge knowledge, technologies, and resources to create advanced diagnostic tools. Collaborations facilitate the integration of various expertise and research capabilities, expediting the development of precise and efficient diagnostic solutions. Through leveraging collective strengths, companies navigate complexities, expanding market presence. These collaborations foster synergy, advancing the progress and acceptance of molecular targeted diagnostics. Consequently, they offer improved diagnostic accuracy and effectiveness, ultimately benefiting healthcare systems and global patients. In February 2023, Thermo Fisher Scientific disclosed that its Applied Biosystems TaqPath PCR kits used in diagnosing infectious diseases like multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27) have obtained licensing approval from the Central Drugs Standard Control Organisation (CDSCO). Thermo Fisher Scientific will collaborate with Mylab Discovery Solutions to produce these kits in India.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.